Bruce Jackson's Stock Ratings

Benchmark Analyst

Bruce Jackson is an analyst at Benchmark. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 11/21/2024

Overall Average Return

-21.0%

Smart Score

Overall Average Return Percentile

11th

Number of Ratings

138

Data brought to you by Benzinga APIs

Recent Analyst Stock Rating News

Deep Dive Into Exact Sciences Stock: Analyst Perspectives (7 Ratings)

Analyst Ratings For Exact Sciences

Expert Ratings For NeoGenomics

Cracking The Code: Understanding Analyst Reviews For Exact Sciences

Wall Street Set For Subdued Start As Traders Await All-Important Inflation Data, Bitcoin Tops $61K: Fund Manager Flags This Event As Pivotal To Near-term Market Recovery

The major index futures are pointing to a nervous start ahead of the consumer price inflation report that is due at 8:30 a.m. EDT. Bond yields are slipping ahead of the inflation data.

Exact Sciences Analysts Slash Their Forecasts After Q2 Results

Movano Evie Ring Could Soon Get FDA Clearance, Analyst Says: 'A Validated Wearable Device Truly Opens The Market'

Movano Evie Ring's generating $1 million in sales during the first 10 days "bodes well for the full commercial launch."

What's Going On With Huamacyte Shares Tuesday?

Humacyte has so far added Dr. John P. Bamforth and Dr. Keith Anthony to its Board of Directors, entered a license agreement with Pluristyx and received Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for its Acellular Tissue Engineered Vessel.

Analyst Scoreboard: 5 Ratings For Clene

Unveiling 4 Analyst Insights On Genelux

The Best Trading Research Platform

For Retail Investors and Professional Trades Alike.

Get Started for Free

Benzinga Pro on Macbook